ctDNA KIT genotyping → TKI selection in GIST
A blood test that reads which resistance mutation a GIST has acquired, so the second drug can be chosen to fit it.
INTRIGUE showed ripretinib far outperformed sunitinib only in KIT exon 11 + 17/18 mutants, while sunitinib was better for exon 13/14; INSIGHT tested this prospectively with ctDNA selection (positive 2026). The first genotype-directed sequencing paradigm in sarcoma.
Pages like this
not linked directly; found by shared links- TrialINVICTUS
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- CompanyDeciphera Pharmaceuticals (Ono)
- TargetPDGFRA
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- PersonCharles D. Blanke
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- ProductPexidartinib
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- ProductPazopanib
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- IdeaWhole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome
Shares Sarcomas (soft tissue, bone, GIST), Liquid biopsy (ctDNA).